01Approach to the Critical Patient/attcp54

Immediate safety assessment

›Psychiatric emergency triggers

›Active suicidal ideation with plan, intent, or means access

›Specific method identified

›Means available at home (firearms, medications)

›Recent suicide attempt within 24 to 72 hours

›Overdose, self-laceration, or other self-injurious act

›Medical stabilization required before psychiatric disposition

›Active homicidal ideation with identified target

›Duty-to-warn obligations apply

›Immediate safety measures and consult

›Psychotic features with mood congruence

›Delusions of guilt, worthlessness, or nihilism

›Command auditory hallucinations to self-harm

›Catatonia or inability to maintain basic self-care

›Stuporous state with mutism or negativism

›Inability to eat, drink, or ambulate

›Medical stabilization priorities

›Airway and aspiration risk in overdose presentation

›GCS < 13: immediate airway assessment

›If TCA overdose, early intubation threshold lowered

›Hemodynamic compromise in overdose

›SBP < 90 mmHg requires IV access and fluid resuscitation

›QRS widening >120 ms in TCA toxicity: sodium bicarbonate IV

›Metabolic derangement as depressive mimic

›Severe hyponatremia (< 125 mmol/l) can present as depressive syndrome

›Hypoglycemia can mimic or worsen affective symptoms

02History/hx96

Core depressive symptoms

›DSM-5 diagnostic criteria (minimum 5 of 9 symptoms for ≥2 weeks)

›Criterion A1: depressed mood most of the day, nearly every day

›Patient-reported sadness, emptiness, hopelessness

›Observer-reported tearfulness or flat affect

›Criterion A2: markedly diminished interest or pleasure (anhedonia)

›Loss of interest in previously enjoyed activities

›Sexual disinterest or loss of motivational drive

›Neurovegetative symptoms

›Significant weight loss (>5% body weight/month) or gain

›Appetite decrease or increase nearly every day

›Insomnia or hypersomnia nearly every day

›Early morning awakening as classic pattern

›Psychomotor agitation or retardation observable by others

›Not merely subjective restlessness or slowness

›Fatigue or loss of energy nearly every day

›Feelings of worthlessness or excessive or inappropriate guilt

›Delusional intensity guilt: psychotic specifier consideration

›Diminished ability to think, concentrate, or indecisiveness

›Recurrent thoughts of death or suicidal ideation

›Passive ideation vs. active ideation with plan

›Frequency, intensity, duration of ideation

›Symptom timeline and severity

›Duration: symptoms present for ≥2 weeks

›Chronicity: single episode vs. recurrent disorder

›Functional impairment assessment

›Occupational functioning: work attendance, productivity

›Social functioning: relationship quality, withdrawal

›ADL capacity: hygiene, nutrition, ambulation

Somatic presentations and atypical features

›Somatic masking in primary care settings

›45 to 95% of MDD patients in primary care initially present with somatic complaints

›Pain syndromes: headache, back pain, diffuse myalgias

›Fatigue and low energy as chief complaint

›GI complaints: nausea, abdominal pain, appetite change

›Atypical depression features

›Mood reactivity (brightens with positive events)

›Hypersomnia rather than insomnia

›Leaden paralysis: heavy, leaden feelings in limbs

›Rejection sensitivity lasting beyond mood episodes

›Prior episode history

›Number of prior depressive episodes

›Recurrence rate: 26% within 1 year, 76% within 10 years of first episode

›Prior treatment response and tolerability profile

›Prior suicide attempts

›Method, lethality, intent, and precipitant

›Prior psychiatric hospitalization

Suicidality risk stratification

›Suicidal ideation characterization

›Ideation type: passive wish to be dead vs. active suicidal ideation

›Active ideation with plan: high risk

›Active ideation without plan: moderate risk requiring assessment

›Columbia Suicide Severity Rating Scale (C-SSRS) domains

›Intensity: frequency, duration, controllability, deterrents, reasons

›Behavior: preparatory acts, self-injurious behavior, aborted attempts

›Access to means

›Firearms in home: most lethal method, highest completion rate

›Stockpiled medications: prescription and OTC quantities

›Risk factors for completed suicide

›Male sex: higher completion rate despite lower attempt rate

›Older age

›Previous suicide attempt: strongest individual predictor

›Substance use comorbidity

›Social isolation and lack of support

›Recent significant loss or stressor

›Family history of suicide

›Approximately 5% of primary care MDD patients report frequent ideation on PHQ-9 item 9

›1% risk of self-harm or suicide attempt within 90 days in this subgroup

Risk factors for MDD

›Demographic and personal risk factors

›Female sex: approximately 2x lifetime prevalence vs. males

›Age of onset: bimodal peaks in young adulthood and midlife

›Family history of MDD: 2 to 4x increased risk

›Heritability approximately 35 to 40%

›Family history of bipolar disorder: screen carefully before starting antidepressants

›Psychosocial and developmental risk factors

›Adverse childhood experiences (ACEs)

›Emotional, physical, or sexual abuse

›Neglect, domestic violence exposure

›Approximately 60% of young adult MDD cases attributable to pre-age-18 risk factors

›Neuroticism and negative affectivity as temperamental trait

›Social determinants: low income, unemployment, food insecurity, social isolation

›Intimate partner violence

›Chronic medical illness: cardiovascular disease, diabetes, cancer, chronic pain, neurologic conditions

›Depressogenic medications history

›Beta-blockers, barbiturates, glucocorticoids, anabolic steroids

›Statins, oral contraceptives, levodopa, methyldopa

›Opioids, fluoroquinolones, mefloquine, metronidazole

›Withdrawal from marijuana, sedatives, opiates, cocaine, or stimulants

Collateral and psychiatric history

›Collateral information sources

›Family or friend corroboration: patients may underreport symptoms

›Social support network assessment

›Living situation and safety of home environment

›Elderly patients particularly likely to underreport depressive symptoms

›Screen for bipolar disorder before antidepressant initiation

›Prior manic or hypomanic episodes

›Decreased need for sleep with elevated energy

›Grandiosity, racing thoughts, impulsive behaviors

›At least 7% of primary care depression patients have unrecognized bipolar disorder

›Antidepressant monotherapy in bipolar disorder can precipitate mania or mixed state

03Physical Exam/exam58

Vital signs and general appearance

›Vital signs relevance in MDD

›Heart rate: tachycardia may suggest anxiety comorbidity or agitation

›Blood pressure: hypertension associated with metabolic comorbidities

›Weight and BMI: significant change from baseline (>5%/month)

›Weight loss: anorexia feature or medical comorbidity

›Weight gain: atypical depression or medication effect

›Temperature: fever suggesting occult medical etiology

›General appearance and behavior

›Psychomotor retardation

›Slowed speech rate and latency of response

›Reduced spontaneous movement, hunched posture

›Flat or blunted affect

›Psychomotor agitation

›Inability to sit still, hand wringing, pacing

›Pressured speech in mixed features or hypomania

›Grooming and hygiene: self-neglect as indicator of severity

›Eye contact: poor or absent in severe depression

›Tearfulness or emotional lability during interview

Mental status examination

›Formal mental status exam components

›Mood: patient's subjective description

›Depressed, sad, empty, irritable, anxious

›Anhedonia verbalization

›Affect: examiner's objective observation

›Flat, blunted, restricted, dysphoric, or labile

›Congruence with stated mood

›Thought content

04Differential Diagnosis/ddx55

Primary psychiatric diagnoses

›Bipolar disorder types

›Bipolar I disorder: manic episode required (ICD-10 F31.x)

›Distinguishing feature: full manic episode lasting ≥7 days

›Antidepressant monotherapy may precipitate mania

›Bipolar II disorder: hypomanic episodes only (ICD-10 F31.81)

›Hypomania: shorter, less severe, no functional impairment

›Often misdiagnosed as MDD for years

›At least 7% of primary care depression patients may have unrecognized bipolar disorder

›Depressive spectrum disorders

›Persistent depressive disorder (dysthymia) (ICD-10 F34.1)

›Depressed mood more days than not for ≥2 years

›Less severe but more chronic than MDD

›Adjustment disorder with depressed mood (ICD-10 F43.21)

›Symptoms within 3 months of identifiable stressor

›Does not meet full MDD criteria

›Premenstrual dysphoric disorder (ICD-10 F32.81)

›Temporal relationship to luteal phase

›Resolves within days of menstruation onset

›Other primary psychiatric diagnoses

›Schizoaffective disorder, depressive type (ICD-10 F25.1)

›Psychotic symptoms present outside mood episodes

›Anxiety disorders with secondary depressive features

›Approximately two-thirds of MDD patients have clinical anxiety

›PTSD with depressive features (ICD-10 F43.10)

›Trauma history with intrusive symptoms and avoidance

Medical and organic etiologies

›Endocrine and metabolic causes

05Laboratory Tests/lt48

Initial workup

›Thyroid function testing

›TSH: first-line thyroid screening for all new MDD presentations

›Hypothyroidism is must-rule-out etiology

›TSH reference range: 0.4 to 4.0 mIU/L

›Subclinical hypothyroidism (TSH 4.0 to 10 mIU/L) may also impair mood

›Free T4 if TSH abnormal

›Complete blood count

›Anemia screening: fatigue and cognitive overlap with MDD

›Hemoglobin < 120 g/L (women), < 130 g/L (men): evaluate etiology

›MCV for B12/folate deficiency (macrocytosis) vs. iron deficiency (microcytosis)

›Leukocytosis: infectious or inflammatory etiology search

›Comprehensive metabolic panel

›Sodium: hyponatremia (< 135 mmol/l) can cause depressive symptoms

›Glucose: hypoglycemia and diabetes screening

›Renal function: BUN and creatinine for medication dosing

›Liver enzymes: alcohol use, hepatotoxicity screening for medications

›Calcium: hypercalcemia (malignancy, hyperparathyroidism) causing depression

Extended diagnostics

›Vitamin levels

›Vitamin B12 level

›Deficiency associated with neuropsychiatric symptoms, depression, cognitive impairment

›Low normal (< 300 pmol/l): consider supplementation

›Folate level

›Low folate associated with antidepressant treatment resistance

›L-methylfolate augmentation strategy in MTHFR polymorphism

›Vitamin D (25-hydroxyvitamin D)

›Deficiency associated with mood disorders in observational studies

06Diagnostic Tests/dt74

Scoring Systems

›PHQ-9 (Patient Health Questionnaire-9)

›Most validated self-report depression screening and severity tool

›Score 1 to 4: minimal depression

›Score 5 to 9: mild depression

›Score 10 to 14: moderate depression

›Score 15 to 19: moderately severe depression

›Score 20 to 27: severe depression

›PHQ-9 performance characteristics

›Sensitivity 88%, specificity 88% at score ≥ 10 cutoff

›Item 9 (suicidality): 5% of primary care patients endorse frequent ideation

›PHQ-2 as ultrabrief initial screen

›Two-item screen: anhedonia and depressed mood

›Sensitivity 83%, specificity 90% for any depressive disorder

›Positive PHQ-2: proceed to full PHQ-9

›Columbia Suicide Severity Rating Scale (C-SSRS)

›Structured suicidality assessment tool

›Ideation subscale: five levels of increasing severity

›Behavior subscale: actual, interrupted, aborted attempts, preparatory acts

›Distinguishes passive ideation from active ideation with intent and plan

›Standardized language for ED and inpatient documentation

›Hamilton Depression Rating Scale (HAM-D)

›Clinician-rated instrument for severity and treatment response

›17-item version most widely used in research

›Score ≥ 20: moderate to severe depression

›Score < 7 after treatment: remission criterion

›Not designed for initial screening: too lengthy for ED

›Geriatric Depression Scale (GDS)

›Validated for depression screening in older adults

›15-item short form: score ≥ 5 suggests depression

›Avoids somatic items that overlap with medical illness in elderly

›Preferred over PHQ-9 in cognitively intact older adults

›Edinburgh Postnatal Depression Scale (EPDS)

›Validated for peripartum depression screening

›Score ≥ 13: positive screen, further evaluation required

›Item 10 screens for self-harm thoughts

›Recommended at all postpartum visits through first year

MRI

›Brain MRI indications in depressive presentations

›First-episode depression with atypical features or age >50

›Focal neurologic signs

›Rapid symptom onset without psychosocial precipitant

›Cognitive impairment out of proportion to mood symptoms

›MRI findings associated with late-life depression

›White matter hyperintensities (WMH) on FLAIR sequences

›Periventricular and deep white matter lesions

›Associated with vascular depression subtype

›Predicts poorer antidepressant response

›Hippocampal volume reduction

›Correlates with MDD duration and episode number

›Partially reversible with successful antidepressant treatment

›Functional MRI (fMRI): research tool, not clinical standard of care

›Altered prefrontal-limbic connectivity demonstrated in MDD

›Hyperactive amygdala response to negative stimuli

CT

›CT head indications in psychiatric emergency

›New-onset psychosis or mania in patients >45 years

›Rule out intracranial mass, hemorrhage, or hydrocephalus

›Acute altered mental status with unclear etiology

›Subdural hematoma presenting as depression in elderly (fall risk)

›Head trauma history with new psychiatric symptoms

›Seizure history with mood symptoms

›Suspected intracranial mass (headache, focal deficits, papilledema)

›CT limitations in MDD workup

›Not indicated for straightforward MDD without neurologic signs

›No sensitivity for white matter disease, small infarcts, or hippocampal changes

›Non-contrast CT adequate for emergency hemorrhage or mass rule-out

Ultrasound

›Thyroid ultrasound

›Indicated when thyroid exam reveals nodule or goiter

›Characterizes nodule morphology for further workup

›Not a primary tool in MDD evaluation

›Abdominal ultrasound

›Hepatic assessment in suspected alcohol-related liver disease

›Not routinely indicated in MDD workup

›Bedside ultrasound in overdose with hemodynamic instability

›Cardiac function assessment: tamponade, systolic dysfunction

›IVC collapsibility for volume status assessment

07Disposition/dispo48

Inpatient psychiatric admission criteria

›Indications for inpatient psychiatric hospitalization

›Active suicidal ideation with specific plan and accessible means

›Firearms in home with suicidal ideation: strong inpatient indication

›When in doubt about safety, inpatient care is the prudent option

›Recent high-lethality suicide attempt

›Medical stabilization required first

›Psychiatric admission after medical clearance

›Active homicidal ideation with identified target or plan

›Psychotic features: delusions or hallucinations with mood episode

›Inability to maintain ADLs or care for self

›Severe catatonia with nutritional compromise

›Extreme self-neglect

›Severe catatonia

›Requires urgent workup and IV lorazepam trial

›Failure of outpatient treatment despite adequate trial

›Medical admission with psychiatric consultation

›Significant overdose requiring medical stabilization

›Concurrent serious medical illness exacerbating depression

›Nutritional compromise requiring IV supplementation

Intermediate care levels

›Partial hospitalization program (PHP) criteria

›Suicidal ideation without intent or plan

›Adequate social support and safe home environment

›Ability to commit to daily attendance

›Recently discharged from inpatient who needs step-down

›Moderate-severe depression with functional impairment

›Intensive outpatient program (IOP) criteria

08Treatment/t138

Acute safety interventions

›Immediate psychiatric emergency management

›Seclusion or restraint

›Physical restraints for imminent danger to self or others when verbal de-escalation fails

›Minimize duration and monitor continuously

›Rapid tranquilization for severe agitation

›Olanzapine 5 to 10 mg IM

›Onset: 15 to 30 minutes

›Avoid within 1 hour of IM lorazepam (respiratory depression risk)

›Haloperidol 5 mg IM plus lorazepam 2 mg IM

›Most evidence for combination in severe agitation

›Monitor for extrapyramidal side effects

›For severe catatonia

›Lorazepam 1 to 2 mg IV challenge test

›Response within 5 to 10 minutes confirms catatonia

›If response: lorazepam 1 to 2 mg TID as bridge to ECT

First-line pharmacotherapy

›SSRI antidepressants (first-line for most patients)

›Escitalopram

›Starting dose: 5 to 10 mg daily

›Target dose: 10 to 20 mg daily

›Ranked highest for both efficacy and acceptability in network meta-analysis

›Favored in elderly and medically complex patients (low drug interactions)

›Sertraline

›Starting dose: 25 to 50 mg daily

›Target dose: 50 to 200 mg daily

›Ranked second for acceptability; first-line in cardiac patients

›Extensive evidence in post-MI depression

›Fluoxetine

›Starting dose: 10 mg daily

›Target dose: 20 to 60 mg daily

›Longest half-life (5 weeks): reduces discontinuation syndrome risk

›Avoid in patients requiring MAOI transition: 5-week washout required

›Common SSRI prescribing principles

›Start at one-third to one-half the usual dose

›Titrate over 1 to 2 weeks

›Optimal efficacy at lower end of licensed dose range (20 to 40 mg fluoxetine equivalents)

›Black box warning: increased suicidal ideation in patients < 25 years

›Early side effects (nausea, headache) typically resolve within 1 to 2 weeks

›SNRI antidepressants

›Venlafaxine

›Starting dose: 37.5 to 75 mg daily

›Target dose: 75 to 225 mg daily

›Serotonin predominant at low doses; norepinephrine effect at ≥150 mg

›Preferred for comorbid anxiety or pain syndromes

›High discontinuation syndrome risk: taper slowly

›Duloxetine

›Starting dose: 30 mg daily

›Target dose: 60 to 120 mg daily

›Indicated for diabetic peripheral neuropathic pain and fibromyalgia comorbidity

›Monitor blood pressure: can elevate BP at higher doses

›Other first-line options

›Bupropion

›Starting dose: 150 mg daily (XL formulation preferred)

›Target dose: 150 to 450 mg daily

›Maximum: 450 mg/day in divided doses; single dose maximum 200 mg to reduce seizure risk

›Advantage: no sexual dysfunction, may aid smoking cessation

›Contraindicated: seizure disorder, bulimia/anorexia nervosa, alcohol or benzodiazepine withdrawal

›Lowers seizure threshold in a dose-dependent manner

›Mirtazapine

›Starting dose: 15 mg at bedtime

›Target dose: 15 to 45 mg at bedtime

›Paradoxically more sedating at lower doses (15 mg > 30 mg)

›Preferred for insomnia, poor appetite, nausea with SSRIs

›Significant weight gain: monitor BMI

Psychotherapy

›Evidence-based psychotherapy options

›Cognitive Behavioral Therapy (CBT)

›Gold standard psychotherapy for MDD: Class I recommendation

›Response rates comparable to antidepressant medication in mild to moderate MDD

›CBT + antidepressant superior to either alone in moderate to severe MDD

›Protects against relapse beyond treatment duration

›Interpersonal Therapy (IPT)

›Focuses on grief, role transitions, interpersonal disputes, social isolation

›Equivalent efficacy to CBT in multiple meta-analyses

›Preferred for depression triggered by interpersonal loss or conflict

›Behavioral Activation

›Behavioral component of CBT as standalone treatment

›Evidence-based for mild to moderate MDD

›More accessible in primary care settings with brief training

›Mindfulness-Based Cognitive Therapy (MBCT)

›Reduces relapse risk in patients with ≥3 prior episodes by 43%

›Class I recommendation for relapse prevention

Augmentation and combination strategies

›Augmentation for partial response (after 4 to 8 weeks at adequate dose)

›Lithium augmentation

›Target serum lithium 0.6 to 0.8 mmol/l

›Response typically within 2 to 3 weeks

›Monitor renal function and TSH every 6 months

›Narrow therapeutic index: toxicity risk at > 1.5 mmol/l

›Second-generation antipsychotic (SGA) augmentation

›Aripiprazole

›Starting dose: 2 to 5 mg daily

›Target dose: 5 to 15 mg daily

›FDA-approved for MDD augmentation

›Watch for akathisia (restlessness): dose-related

›Quetiapine XR

›Starting dose: 50 mg at bedtime

›Target dose: 150 to 300 mg daily

›FDA-approved for MDD augmentation

›Metabolic monitoring: weight, glucose, lipids

›Brexpiprazole

›Starting dose: 0.5 to 1 mg daily

›Target dose: 2 to 3 mg daily

›Lower akathisia rate than aripiprazole

›Thyroid hormone augmentation

›Triiodothyronine (T3) 25 to 50 mcg daily

›Evidence primarily in TCA-based trials

›Monitor thyroid function during use

›L-methylfolate

›15 mg daily for patients with MTHFR polymorphism

›Augments monoamine synthesis via tetrahydrobiopterin pathway

›Well-tolerated with low adverse effect burden

Treatment-resistant depression

›Definition and threshold

›Treatment-resistant depression (TRD): failure of ≥2 adequate antidepressant trials

›Adequate trial: therapeutic dose for ≥4 to 6 weeks

›Up to 30 to 40% of patients fail initial antidepressant treatment

›Advanced interventions

›Esketamine (Spravato) intranasal

›56 mg or 84 mg intranasally twice weekly for 4 weeks

›FDA-approved for TRD and MDD with acute suicidal ideation (MDSI)

›Must be administered in certified healthcare setting (REMS program)

›Dissociative side effects: monitor for 2 hours post-dose

›Rapid onset of effect within hours: advantage in acute suicidality

›Transcranial magnetic stimulation (rTMS)

›NNT 5 to 7 for remission vs. sham

›30 to 36 sessions over 6 to 9 weeks

›First-line for TRD patients who prefer to avoid medications

›Contraindicated with cochlear implants or intracranial ferromagnetic metal

›Electroconvulsive therapy (ECT)

›Most effective intervention for severe, refractory MDD

›Remission rates 70 to 90% in severe/refractory depression

›Indications: catatonia, psychotic depression, severe suicidality, need for rapid response

›Cognitive side effects: anterograde and retrograde amnesia (usually transient)

›Requires anesthesia and brief generalized seizure induction

Maintenance treatment

›Duration of pharmacotherapy after remission

›First episode: continue antidepressant for ≥6 months after remission

›Second episode: continue for ≥2 years

›Three or more episodes or severe episodes: consider indefinite maintenance

›Taper antidepressants slowly over ≥4 weeks to minimize discontinuation syndrome

›Discontinuation syndrome risk highest with paroxetine and venlafaxine

›Symptoms: dizziness, electric shock sensations, nausea, irritability

09Special Populations/sp84

Pregnancy

›Peripartum depression considerations

›Prevalence of MDD during pregnancy and postpartum

›Affects 10 to 15% of women in perinatal period

›Postpartum depression (PPD): onset within 4 weeks of delivery; may extend to 1 year

›Edinburgh Postnatal Depression Scale (EPDS) score ≥ 13: positive screen

›Risks of untreated MDD in pregnancy

›Preterm birth and low birth weight

›Inadequate prenatal care attendance

›Impaired mother-infant bonding

›Neonatal abstinence if medication used vs. risks of untreated depression

›Antidepressant safety in pregnancy

›SSRIs: generally considered first-line; best safety profile

›Sertraline and escitalopram preferred: low placental transfer

›Avoid paroxetine in first trimester: associated with cardiac malformations (Category D)

›Persistent pulmonary hypertension of newborn (PPHN): small increased risk with SSRI in third trimester

›Neonatal adaptation syndrome with SSRI use near term

›Irritability, tremor, poor feeding, respiratory distress in neonate

›Usually mild and self-limited within 2 weeks

›Not a reason to discontinue antidepressant: weigh risks of relapse

›Brexanolone (Zulresso)

›FDA-approved specifically for postpartum depression

›IV infusion over 60 hours in certified healthcare setting

›Rapid onset (within 24 hours) vs. weeks for standard antidepressants

›REMS program required due to excessive sedation risk

›ECT in pregnancy

›Safe in all trimesters for severe, refractory, or psychotic depression

›Requires obstetric monitoring and anesthetic modifications

›Preferred over medication changes in severely ill pregnant patients

›Psychotherapy as preferred first-line in mild to moderate peripartum MDD

›CBT and IPT with strong evidence in peripartum populations

›Particularly suitable for patients who prefer to avoid medications

Geriatric

›Late-life depression characteristics

›Prevalence: 1 to 5% in community-dwelling older adults; 5 to 12% in medical settings

›Underrecognized and undertreated in this population

›Atypical presentations in older adults

›Somatic complaints predominate over mood complaints

›Cognitive symptoms (pseudodementia) may be chief concern

›Irritability more common than sadness

›Anhedonia and apathy may be misattributed to aging

›Vascular depression subtype

›White matter hyperintensities on MRI associated with late-onset depression

›Poorer antidepressant response and higher relapse rate

›Cardiovascular risk factor management important

›Medication considerations in older adults

›Preferred agents

›Escitalopram: preferred SSRI; minimal drug interactions; well-tolerated

›Sertraline: preferred in cardiac comorbidity

›Mirtazapine: useful for insomnia, poor appetite, and weight loss

›Agents to avoid (Beers Criteria)

›Paroxetine: high anticholinergic burden, falls risk, cognitive effects

›TCAs (amitriptyline, nortriptyline): orthostasis, cardiac conduction effects, anticholinergic burden

›Benzodiazepines for anxiety comorbidity: fall and delirium risk

›Dosing principles

›Start low, go slow: begin at 25 to 50% of standard adult dose

›Drug interactions: CYP2D6 and CYP3A4 metabolism in polypharmacy context

›ECT highly effective in older adults

›Remission rates 50 to 70% in elderly TRD

›Cognitive side effects require careful monitoring

›Preferred in severe MDD with food refusal or active suicidality

Pediatrics

›Depression in children and adolescents

›Prevalence: 1 to 2% in children, 3 to 8% in adolescents

›Adolescent female to male ratio: 2:1 (same as adults post-puberty)

›Onset commonly in early adolescence (12 to 15 years)

›Presentation differences from adults

›Irritability may replace depressed mood (DSM-5 allows this in <18)

›Somatic complaints: headaches, stomachaches common

›School refusal and academic decline

›Withdrawal from peers and extracurricular activities

›Impulsivity and behavioral problems in younger children

›Pharmacotherapy in pediatric MDD

›FDA-approved agents for pediatric MDD

›Fluoxetine: approved for ages ≥8 years (depression) and ≥7 years (OCD)

›Starting dose: 10 mg daily; target 20 to 40 mg daily

›Escitalopram: approved for ages ≥12 years

›Starting dose: 5 to 10 mg daily; target 10 to 20 mg daily

›Black box warning applies: increased suicidal ideation and behavior in patients < 25

›Particularly elevated risk in first 1 to 4 weeks of treatment

›Weekly monitoring initially, then biweekly for first month

›Avoid paroxetine in pediatric patients: lack of efficacy and increased suicidality signal

›Psychotherapy as first-line in mild to moderate pediatric MDD

›CBT with strong evidence base in adolescent MDD

›Family-based interventions for younger children

›CBT + SSRI (TADS trial): superior to either alone in moderate to severe adolescent MDD

›NNT for combination vs. placebo: 2

10Background/b86

Epidemiology

›Prevalence and incidence

›Global prevalence of MDD: 4.4% of world population (WHO 2017)

›Approximately 300 million people affected worldwide

›Leading cause of disability globally

›Lifetime prevalence: 15 to 20% in high-income countries

›12-month prevalence: 7 to 10% in United States general population

›Female to male ratio: approximately 2:1

›Hormonal, social, and reporting factors contribute

›Disease burden and mortality

›MDD is the leading cause of disability-adjusted life years (DALYs) in mental health globally

›Suicide mortality: 30,000 to 45,000 deaths annually in the United States

›MDD present in 40 to 60% of completed suicides

›Medical comorbidity impact

›MDD increases mortality from cardiovascular disease by 2x

›MDD doubles risk of myocardial infarction in prospective cohorts

›Depression worsens outcomes in diabetes, cancer, and chronic pain

›Recurrence and chronicity

›Recurrence rate: 26% within 1 year after remission

›Recurrence rate: 76% within 10 years after first episode

›Each subsequent episode increases recurrence risk and duration

›Up to 30% of MDD patients develop chronic course (>2 years without remission)

Pathophysiology

›Monoamine hypothesis

›Serotonin deficiency theory

›SSRIs increase synaptic serotonin by blocking reuptake transporter (SERT)

›5-HT1A receptor autoinhibition: initial activation limits response (explains delayed effect)

›Desensitization of 5-HT1A autoreceptors: required for full antidepressant effect (2 to 4 weeks)

›Norepinephrine and dopamine pathways

›Norepinephrine: attention, energy, motivation

›Dopamine: anhedonia, reward processing, motivation

›Dopamine reward circuit hypoactivity: explains anhedonia

›HPA axis dysregulation

›Hypercortisolemia in melancholic and severe MDD

›CRH overproduction from hypothalamus

›Cortisol impairs hippocampal neurogenesis

›Hippocampal volume loss proportional to cumulative depression burden

›Dexamethasone suppression test (DST) non-suppression in severe MDD

›Historical interest; not used clinically for diagnosis

›Neuroplasticity and BDNF hypothesis

›Brain-derived neurotrophic factor (BDNF)

›Reduced BDNF in MDD: impaired hippocampal neurogenesis

›Antidepressants increase BDNF expression over weeks

›Explains 2 to 4 week delay in antidepressant response

›Ketamine's mechanism of action

›NMDA receptor antagonism: rapid glutamatergic burst

›Immediate BDNF and AMPA receptor upregulation

›Explains hours-to-days onset vs. weeks for SSRIs

›Inflammatory hypothesis

›Elevated pro-inflammatory cytokines (IL-6, TNF-alpha, CRP) in MDD

›Sickness behavior model: anhedonia, fatigue, social withdrawal as immune-mediated

›Anti-inflammatory strategies under investigation

›Gut-brain axis

›Dysbiosis associated with MDD in observational studies

›Vagal nerve signaling from gut microbiome to CNS

Therapeutic Considerations

›Antidepressant selection framework

›First-line: SSRIs (escitalopram, sertraline) for most patients

›Consider comorbidities: pain (SNRIs), insomnia (mirtazapine), smoking cessation (bupropion)

›Prior response: use previous effective agent if well-tolerated

›Drug interactions: CYP450 profile of patient's other medications

›Treatment response monitoring

›Expect 50% response within 4 to 6 weeks at adequate dose

›If no benefit after 4 weeks at adequate dose: consider switching or augmenting

›If partial response: augmentation preferred over full switch

›Measurement-based care

›PHQ-9 at every visit: objective tracking of response

›Remission: PHQ-9 < 5 and no functional impairment

›Response: ≥50% reduction in PHQ-9 from baseline

›Serotonin syndrome awareness

›Risk factors

›Combining two or more serotonergic agents

›SSRI/SNRI + tramadol, linezolid, methylene blue, triptans, fentanyl (weak)

›SSRI/SNRI + MAOI: absolute contraindication (potentially fatal)

›Clinical features

›Hunter criteria: clonus (most sensitive/specific), agitation, diaphoresis, tremor, hyperreflexia

›Hyperthermia >41.1 degrees C in severe cases

›Management

›Discontinue offending agents immediately

›Cyproheptadine 12 mg PO/NG then 2 mg q2h up to 32 mg/day

›Benzodiazepines for agitation and temperature control

›MAOI considerations

›Phenelzine, tranylcypromine: reserved for refractory MDD or atypical depression

›Dietary tyramine restriction required: hypertensive crisis risk

›Washout period: 2 weeks before starting another serotonergic agent

›Fluoxetine washout: 5 weeks before MAOI initiation

›Selegiline transdermal patch: selective MAO-B inhibitor at low doses

›6 mg/24h patch: dietary restrictions may not be required

›Fewer drug interactions than oral MAOIs

11Patient Discharge Instructions/pdi40

copy discharge instructions

›Diagnosis and basic information

›You have been evaluated and the diagnosis is major depressive disorder (MDD)

›This is a medical condition affecting brain chemistry, mood, and function

›Treatment is effective: most people improve with the right medication and therapy

›Your treatment plan today

›Prescription provided: take as directed, do not stop suddenly

›Follow-up appointment: scheduled within 7 days

›Referral for psychotherapy if not already engaged

›Medication instructions

›Start antidepressant at the low dose provided and take every day

›It may take 2 to 4 weeks before you notice improvement in mood

›Side effects like nausea or headache in the first 1 to 2 weeks are common and usually pass

›Do not stop your antidepressant without talking to your doctor first

›Stopping suddenly can cause dizziness, electric shock sensations, and worsening mood

›If you decide to stop, your doctor will create a slow tapering plan

›Alcohol and recreational drugs worsen depression and interfere with medications

›Avoid alcohol completely while on antidepressants

›Safety planning

›If you have thoughts of hurting yourself, call 988 (Suicide and Crisis Lifeline) immediately

›Available 24 hours a day, 7 days a week

›You can also text 988

›Remove or secure dangerous items at home

›Lock firearms in a gun safe or store outside the home

›Dispose of extra medications or give them to a family member to hold

›Your safety contact person: ask a trusted person to check in daily for the next 2 weeks

›Return to emergency department immediately if

›You are having thoughts of suicide with a plan or intent to act

12References/r36

Guidelines and key sources

›DSM-5-TR: Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition Text Revision

›American Psychiatric Association (2022)

›Diagnostic criteria for MDD, bipolar disorders, and differential diagnosis framework

›RANZCP Clinical Practice Guidelines for Mood Disorders

›Malhi GS, Bell E, Singh AB et al., Bipolar Disorders (2020)

›Evidence-based framework for MDD assessment and pharmacotherapy

›VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder

›Department of Veterans Affairs and Department of Defense (2022)

›Stepwise management algorithm for MDD in primary care and specialty settings

›ACP Living Clinical Guideline: Nonpharmacologic and Pharmacologic Treatments of Adults in the Acute Phase of MDD

›Qaseem A et al., Annals of Internal Medicine (2023)

›Class I recommendation for CBT and SSRIs as first-line treatment

›JAMA Review: Management of Depression in Adults

›Simon GE, Moise N, Mohr DC, JAMA (2024)

›Comprehensive evidence synthesis for pharmacotherapy and psychotherapy

›Lancet Review: Major Depressive Disorder

›Malhi GS, Mann JJ, Lancet (2018)

›Pathophysiology, epidemiology, and treatment-resistant strategies

Landmark trials and scoring tools

›PHQ-9 validation study

›Kroenke K, Spitzer RL, Williams JB, Journal of General Internal Medicine (2001)

›PHQ-9 sensitivity 88%, specificity 88% at score ≥10 cutoff

›STAR*D trial

›Rush AJ et al., NEJM (2006)

›Up to 70% of patients fail initial antidepressant; stepwise augmentation strategy

›TADS trial: adolescent MDD

›March J et al., JAMA (2004)

Evidence & Review